Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $988000.0.

  • Axsome Therapeutics' Free Cash Flow rose 10527.75% to $988000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.4 million, marking a year-over-year increase of 2365.96%. This contributed to the annual value of -$128.7 million for FY2024, which is 1165.85% up from last year.
  • Axsome Therapeutics' Free Cash Flow amounted to $988000.0 in Q3 2025, which was up 10527.75% from -$32.4 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Free Cash Flow high stood at $988000.0 for Q3 2025, and its period low was -$55.5 million during Q2 2023.
  • Moreover, its 4-year median value for Free Cash Flow was -$30.4 million (2023), whereas its average is -$31.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 80911.41% in 2024, then skyrocketed by 10527.75% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Free Cash Flow (Quarter) stood at -$27.7 million in 2022, then dropped by 9.46% to -$30.4 million in 2023, then rose by 13.62% to -$26.2 million in 2024, then surged by 103.77% to $988000.0 in 2025.
  • Its Free Cash Flow stands at $988000.0 for Q3 2025, versus -$32.4 million for Q2 2025 and -$43.7 million for Q1 2025.